-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 20, China's antibody drug pioneer Sansheng Guojian announced that Numab Therapeutics, the company invested by the company, today completed a 100 million Swiss franc (approximately US$110 million) Series C financing
.
This round of financing was jointly led by Novo Ventures and HBM Partners, the venture capital arm of Novo Holdings.
In 2020, 3SBio Group led the investment of Numab's 22 million Swiss francs (approximately US$22.
6 million) Series B financing
.
Prior to this, the two parties reached an agreement that Sansheng Guojian will develop and commercialize a series of new multispecific antibodies for cancer treatment based on Numab's technology platform
Compared with traditional tumor immunotherapy, multispecific antibodies are expected to open up a new treatment model with a higher risk-benefit ratio
.
Numab's patented MATCH™ technology platform is one of the most versatile and flexible multispecific antibody development platforms
Dr.
Jing Lou, Chairman of Sansheng Guojian said: "Congratulations to Numab for completing the C round of financing.
Numab has a leading multi-specific antibody technology platform and a series of tumor immune products.
The successful completion of the C round of financing demonstrates Numab's advanced capabilities.
